A boost for the precision of genome editing
August 20, 2025
Researchers develop a fast-acting, cell-permeable protein system to control CRISPR-Cas9, reducing off-target effects and advancing gene therapy.
Researchers develop a fast-acting, cell-permeable protein system to control CRISPR-Cas9, reducing off-target effects and advancing gene therapy.
Cepheid announced that the test will be shipped to Canadian customers this month.
Signos today announced a major step forward in bringing over-the-counter (OTC) continuous glucose monitoring (CGM) to market.
Microbot Medical (Nasdaq:MBOT) announced today that it received a new patent covering a modular robotic surgical system.
OSTRAVA, Czech Republic, Aug. 19, 2025 /PRNewswire/ — Stimvia, a medtech company based in the Czech Republic, has successfully completed a clinical study on peroneal electrical transcutaneous neuromodulation (peroneal eTNM®) through its URIS® device to treat Parkinson’s disease symptoms.
Datasea, a Nevada-based technology enterprise specialising in advanced acoustic high-tech products and AI multimodal digital solutions, today announced a milestone breakthrough in its acoustic technology
West Nile virus (WNV) has been the dominant cause of mosquito-borne illness in the United States since its introduction into North America in 1999. There are no vaccines nor medications to prevent or treat illness in people, so surveillance, prevention, and control remain the best options to protect the public.
A hybrid reading strategy for screening mammography, developed by Dutch researchers and deployed retrospectively to more than 40,000 exams, reduced radiologist workload by 38% without changing recall or cancer detection rates.
A team of researchers at the University of Oxford have unveiled a pioneering “microstent” which could revolutionize treatment for glaucoma, a common but debilitating condition. The study has been published in The Innovation.
By analyzing millions of messenger RNA molecules (mRNA) during the course of ALS, researchers at Stockholm University, in collaboration with scientists at the Paris Brain Institute and Örebro University, have identified why certain nerve cells are resistant to the disease and what happens in the sensitive nerve cells when they are affected.